379 related articles for article (PubMed ID: 10575140)
1. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
3. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
4. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of quinolone resistance in Staphylococcus aureus.
Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
[TBL] [Abstract][Full Text] [Related]
6. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
7. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
8. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
[TBL] [Abstract][Full Text] [Related]
11. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
Noguchi N; Okihara T; Namiki Y; Kumaki Y; Yamanaka Y; Koyama M; Wakasugi K; Sasatsu M
Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
Muñoz Bellido JL; Alonso Manzanares MA; Yagüe Guirao G; Gutiérrez Zufiaurre MN; Toldos MC; Segovia Hernández M; Garcia-Rodríguez JA
Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
16. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
[TBL] [Abstract][Full Text] [Related]
17. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
[TBL] [Abstract][Full Text] [Related]
18. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
Wang T; Tanaka M; Sato K
Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
Ferrero L; Cameron B; Crouzet J
Antimicrob Agents Chemother; 1995 Jul; 39(7):1554-8. PubMed ID: 7492103
[TBL] [Abstract][Full Text] [Related]
20. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
Schmitz FJ; Fluit AC; Lückefahr M; Engler B; Hofmann B; Verhoef J; Heinz HP; Hadding U; Jones ME
J Antimicrob Chemother; 1998 Dec; 42(6):807-10. PubMed ID: 10052906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
